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ABSTRACT
Introduction Venous leg ulceration (VLU), the most 
common type of chronic ulcer, can be difficult to heal 
and is a major cause of morbidity and reduced quality 
of life. Although compression bandaging is the principal 
treatment, it is time- consuming and bandage application 
requires specific training. There is evidence that 
intervention on superficial venous incompetence can help 
ulcer healing and recurrence, but this is not accessible 
to all patients. Hence, new treatments are required to 
address these chronic wounds. One possible adjuvant 
treatment for VLU is human decellularised dermis (DCD), a 
type of skin graft derived from skin from deceased tissue 
donors. Although DCD has the potential to promote ulcer 
healing, there is a paucity of data for its use in patients 
with VLU.
Methods and analysis This is a multicentre, parallel 
group, pragmatic randomised controlled trial. One hundred 
and ninety- six patients with VLU will be randomly assigned 
to receive either the DCD allograft in addition to standard 
care or standard care alone. The primary outcome is the 
proportion of participants with a healed index ulcer at 
12 weeks post- randomisation in each treatment arm. 
Secondary outcomes include the time to index ulcer 
healing and the proportion of participants with a healed 
index ulcer at 12 months. Changes in quality of life scores 
and cost- effectiveness will also be assessed. All analyses 
will be carried out on an intention- to- treat (ITT) basis. 
A mixed- effects, logistic regression on the outcome of 
the proportion of those with the index ulcer healed at 12 
weeks will be performed. Secondary outcomes will be 
assessed using various statistical models appropriate to 
the distribution and nature of these outcomes.
Ethics and dissemination Ethical approval was granted 
by the Bloomsbury Research Ethics Committee (19/
LO/1271). Findings will be published in a peer- reviewed 
journal and presented at national and international 
conferences.
Trial registration number ISRCTN21541209.
INTRODUCTION
Background and rationale
Venous leg ulceration (VLU) describes a 
persistent wound in the lower limbs caused 
by a poorly functioning venous system. Char-
acterised by chronicity and a protracted and 
intensive treatment, these wounds affect 
approximately 1%–2% of the population, 
with prevalence increasing to up to 4% in 
those over 65 years of age.1 2
VLU has a devastating impact on quality of 
life (QoL) and social function especially in 
Strengths and limitations of this study
 ► This is the first randomised controlled trial evaluat-
ing the use of the decellularised dermis (DCD) al-
lograft solely in patients with venous leg ulceration 
(VLU).
 ► The cost- effectiveness analysis will assess the 
economic impact of using the DCD allograft for the 
management of patients with VLU.
 ► This is a pragmatic study hence compression and 
debridement technique will be up to local guide-
lines/standard care.
 ► This study only evaluates applications in patients 
with chronic venous ulceration.
 ► This study does not address long- term recurrence 
rates beyond 1 year.
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the elderly.3–5 The wounds can be very painful, resulting in 
reduced mobility, and require regular dressing changes, 
which can be extremely painful and time- consuming. 
Together, these factors result in negative QoL effects as 
severe as those seen in other life- limiting chronic condi-
tions, such as congestive cardiac failure and chronic 
obstructive pulmonary disease.6
VLU presents a significant burden to the healthcare 
service.7 Up to 50% of district nurse time is spent caring 
for people with chronic wounds, of which 70% will be 
venous in origin.8 9 Furthermore, ulcers can recur many 
times with up to 48% recurring at 5 years, thus requiring 
further treatment.10 11 Combined with the social cost 
due to loss of work and productivity, VLU is estimated 
to cost up to 2% of the annual healthcare budget, which 
equates to approximately £2.5 billion in the UK in 2017.12 
This is predicted to increase as a result of the ageing 
population.13
The management of chronic VLU is therefore an 
important priority and public health concern. Compres-
sion, in the form of bandaging and stockings, is the under-
lying principle of treatment, with the aim of reducing 
venous hypertension.14 However, applying compression 
is time- consuming; bandage application requires skill 
and stockings are not suitable for everyone.14 15 Further-
more, the reduction in community nursing numbers has 
resulted in increasing difficulty for patients to access this 
service.16 17
Evidence from the ESCHAR and EVRA trials shows that 
interventions to abolish superficial venous incompetence 
improve ulcer healing and recurrence.8 18 Although prom-
ising, such intervention is not accessible to all patients.19 
Moreover, although EVRA reported that early interven-
tion performed in ulcers with a duration of less than 6 
months was beneficial, many patients present within leg 
ulceration of greater duration than this, recurrent ulcer-
ation despite eradication of venous incompetence or 
may have underlying deep venous incompetence. These 
chronic wounds are known to be hard to heal and require 
considerable nursing resources.10 20 The current treat-
ments offered are therefore insufficient for the manage-
ment of VLU.
Skin grafting represents an adjuvant treatment that 
can promote and expedite ulcer healing.21 Grafts can be 
taken from the patient’s own skin, from a donor or from 
tissue- engineered skin.22 An autograft (graft from own 
skin) can be performed in different ways, including pinch 
and punch grafting, mincing and meshing.23 Despite 
promoting ulcer healing, drawbacks exist, including poor 
cosmetic outcomes and the need for a formal surgical 
procedure in an operating theatre in some instances.24 25 
Furthermore, surgical waiting lists can be lengthy and, in 
the current National Health Service (NHS) climate, bed 
availability is not guaranteed.26 Thus, routine autografts 
are not accessible to all patients with ulcer. Allografts 
(donor skin) and xenografts (animal skin) have been 
successfully employed, but present similar drawbacks 
to autografts and the potential for immunogenicity and 
disease transmission.27 Tissue- engineered skin is donor 
skin that has been processed to be made inert, and there-
fore is not immunogenic.28 A Cochrane review found that 
tissue- engineered skin in conjunction with compression 
increased the healing rate in venous ulceration; however, 
there was insufficient evidence to determine the effective-
ness of any other skin graft material.29
Human decellularised dermis (DCD) is generated from 
skin donations from deceased tissue donors processed 
to remove epidermal and dermal cells while preserving 
dermal structures and is supplied nationally by the NHS 
Blood and Transplant (NHSBT).30 31 This provides an 
immunologically inert scaffold to support cellular repop-
ulation and tissue revascularisation. Although allografts 
can only serve as temporary cover, the advantage of the 
DCD allograft is that it can be applied to the wound with 
local anaesthesia (via tissue staples or sutures) or without 
(via tissue glue), and therefore does not require admis-
sion for a procedure under general anaesthetic. The 
procedure can be performed in the outpatient depart-
ment, avoiding inpatient admission and theatre use, 
making the technique more accessible to a larger group 
of patients.
The majority of DCD studies, including randomised 
controlled trials, have been performed in populations 
with diabetes.32–35 DCD allografts have been reported 
as safe, to promote angiogenesis36 and, in randomised 
controlled trials, to significantly reduce ulcer healing 
time (by up to 50%).37 38 Cohort study data reveal a reduc-
tion in wound surface area, improved healing in venous 
ulceration, with evidence of angiogenesis, host cell migra-
tion and proliferation.39 This study addresses the lack 
of robust research evidence about the effects of DCD 
allografts on VLU healing.
This prospective, randomised, open (non- blinded), 
pragmatic trial will explore whether the DCD allograft in 
addition to standard care, compared with standard care 
alone, will improve healing rates, reduce recurrence, 
increase ulcer- free time and improve QoL for those with 
VLU. In addition, a cost- effectiveness analysis will be 
performed to assess the economic impact of using the 
DCD allograft for the management of this patient popula-
tion, whose care consumes significant financial resource.
Currently, the annual cost to conservatively manage 
VLU is approximately £1200 per patient14 ; however, in 
chronic ulceration this is likely to be more. The NHS per 
patient costs for graft application will be approximately 
£400. If a positive outcome results from this trial, the 
reduced ulcer healing time will likely result in signifi-
cantly reduced NHS costs with an improvement in quality- 
adjusted life years (QALYs).
Objectives
The primary objective is to determine whether the use 
of the DCD allograft in patients with VLU, in addition to 
standard care, improves healing at 12 weeks compared 
with standard care alone. Secondary objectives include 
comparisons of time to ulcer healing, change in ulcer 
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This is a prospective, randomised, open (non- blinded), 
pragmatic trial with a follow- up of 12 months.
Study setting
Eligible participants will be recruited from at least 10 sites 
in the UK. A full list of the study sites can be found on 
the International Standard Randomised Controlled Trial 
Number registry.40
Eligibility criteria
Inclusion criteria are: adult patients (>18 years), able 
to provide informed consent with a diagnosis of VLU 
with documented evidence of venous incompetence on 
duplex ultrasound, ulcer duration for >6 months and 
ulcer surface area ≥2 cm2. Where there is more than 
one ulcer present, the largest ulcer will be chosen as 
the index ulcer for the purposes of the trial. Exclusion 
criteria include: a diagnosis of sickle cell disease, an 
Ankle Brachial Pressure Index <0.8, a clinically infected 
ulcer, treatment with biomedical or topical growth factors 
within the previous 30 days, and a history of an inability to 
tolerate compression therapy or a foot ulcer (ie, below the 
ankle). The DCD allograft preparation entails the use of 
a number of components, including specific antibiotics, 
which are then washed away. There have been no docu-
mented allergic or hypersensitivity reactions to the DCD 
graft reported. Patients with known allergies to the DCD 
preparation components are therefore able to participate 
at the discretion of the clinical team.
Interventions
All eligible patients will be informed about the study and 
provided with a written information sheet. Consenting 
participants will be randomised to receive either the 
DCD allograft in addition to standard care or standard 
care alone (figure 1). Baseline demographic data will be 
collected for each participant, including details of their 
medical history and any concomitant medication. The 
EQ- 5D41 and Charing Cross Venous Ulceration Question-
naire (CCVUQ)42 will also be completed for generic and 
disease- specific QoL assessment, respectively.
Participants in the standard care arm will undergo 
wound cleaning and debridement, plus standard 
compression therapy in the form of multilayer elastic 
compression bandaging or stockings. Participants in the 
DCD arm will undergo wound cleaning and debride-
ment and DCD allograft application. The DCD graft 
will be applied by trained registered healthcare profes-
sionals (physicians or nurses). Training on the appli-
cation of the DCD graft will be provided by NHSBT. 
The DCD will be applied to the debrided index ulcer 
wound bed. Recommendations will be made that the 
DCD should be secured with surgical glue, staples and/
or sutures to optimise graft adhesion. The DCD graft 
should be fenestrated liberally with a scalpel or scissors 
to allow wound exudate to pass through to reduce risk of 
seroma/haematoma developing under DCD. Following 
application of the DCD allograft, a non- adhesive, non- 
absorbent, non- medicated primary dressing will be 
applied, followed by the appropriate bolster/secondary 
dressings.31 Compression therapy will then be applied 
according to local practice and may include multilayer 
elastic compression bandaging or stockings delivering 
20–40 mm Hg pressure. Practice/district nurses will be 
advised not to change the primary dressing the first 7 
days post- DCD allograft application. If the DCD allograft 
has not adhered to the wound bed at the 1- week visit, 
the graft can be rinsed in saline (if it appears viable) and 
reapplied and resecured. Additional grafts will not be 
reapplied as part of the trial.
As this is a pragmatic trial, the ulcer care in both arms 
will be as per local unit standard practice. All participants 
will have their ulcers irrigated, cleaned and debrided 
according to best local practice. Compression therapy will 
be according to local practice and may include multilayer 
elastic compression bandaging or stockings designed 
to deliver between 20 and 40 mm Hg pressure. Wound 
dressing and compression application will be performed 
by trained research nurses or community/district/prac-
tice nurses as per standard care. In the event of a missed 
visit, local study teams will liaise with/ask the participant 
to liaise with the district/community/practice nurse to 
arrange dressing change and compression application. 
The use of negative pressure wound therapy device will be 
left to the discretion of the treating clinician. All partic-
ipants may be offered interventional procedures in the 
form of endovenous ablation (in the presence of superfi-
cial venous disease) dependent on whether local recruit-
ment site practice is to intervene on ulcers over 6 months’ 
duration. Once the wound has healed, the participant 
will be given a minimum of class II compression hosiery 
(18–24 mm Hg) to wear to prevent ulcer recurrence as 
per local practice. Endovenous ablation, among other 
procedures, at any point post- randomisation, will be 
recorded at the 12- month follow- up.
Primary outcome
The primary outcome is the proportion of participants 
with a healed index ulcer assessed with ulcer photog-
raphy at 12 weeks after randomisation.
Secondary outcomes
The secondary outcomes include:
 ► Time to index ulcer healing from randomisation.
 ► The percentage change in index ulcer area at 12 
weeks from randomisation.
 ► The proportion of participants with a healed index 
ulcer at 12 months from randomisation.
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Figure 1 Flow diagram of the study protocol. CCVUQ, Charing Cross Venous Ulceration Questionnaire; CVU, chronic venous 
ulceration; DCD, decellularised dermis.
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 ► The proportion of those whose index ulcer healed for 
whom an ulcer recurred at the index site within 12 
months from randomisation.
 ► Change in QoL score at 12 weeks, 6 months and 12 
months from randomisation using the EQ- 5D and 
CCVUQ.
 ► Cost- effectiveness analysis, measured using the incre-
mental cost- effectiveness ratio (ICER).
Sample size and study duration
To detect an absolute difference of 25% in the propor-
tion of participants with a healed index ulcer at 12 weeks 
(assuming a healing rate of 30% in the control group and 
55% in the intervention group) and allowing for a 10% 
loss to follow- up with a power of 90% and 5% level of 
significance, 196 patients are required (Stata/IC V.15.1 
for Mac, Statacorp, College Station, Texas, USA; proce-
dure ‘power twoprop’, with continuity correction). The 
effect size was estimated from previously published litera-
ture on diabetic and venous ulceration, showing an abso-
lute difference in the proportion of participants with a 
healed ulcer of 25% between intervention and control 
groups at 12 weeks.32 38 39 With the 12- month follow- up, 
this study will run for 36 months.
Interim analysis
When we have mature 12- week primary outcome data 
on the first 50 participants randomised, we will review 
the sample size with the independent Trial Steering 
Committee (TSC) on the basis of recruitment rate, the 
overall (blinded) primary outcome of index ulcer healed 
proportion (expected to be (30+55/2)=~40%) and attri-
tion rate (expected to be 10%).
We plan on having a formal interim analysis with the 
possibility of stopping early for futility (no prospect 
of a clinically meaningful treatment effect, or for over-
whelming evidence of effectiveness) at this point (of n=50 
with mature primary outcome data, or at around 25% of 
the total scheduled events observed). This single interim 
analysis using a Lan- DeMets alpha spending approach 
with Fleming O’Brien boundaries has negligible effect on 
the required sample size (R V.3.4.1 for Windows, package 
gsDesign).
Recruitment
Potential participants will be identified at outpatient clinic 
appointments. Posters and leaflets will also be displayed 
in the outpatient clinics and other appropriate locations.
Potentially eligible patients will receive a verbal expla-
nation of the study and a patient information sheet by the 
attending clinical/research team.
Randomisation
Consent forms are completed on the day of treatment. 
Following confirmation of eligibility, consent and 
completion of baseline assessments, participants will 
then be randomly allocated to receive one of the two 
possible treatment options using an online computerised 
web system (REDCap, managed by the study data centre, 
University of Edinburgh). A minimisation algorithm 
using centre, index ulcer size and duration will be used, 
including a random component to lessen predictability.
Blinding
As the DCD allograft is visible after application for a 
period of time, it is not possible to mask participants or 
the research/clinical teams to the treatment strategy. 
However, the primary outcome assessments (verification 
of index ulcer healing visits) will be completed by an 
independent clinical assessor trained in the assessment 
of wound healing, who will have no previous involvement 
with, or knowledge of, the participant’s index ulcer treat-
ment and as such will be blind to the randomised treat-
ment strategy (the DCD allograft is not expected to be 
visible after 4 weeks).
Follow-up periods
All participants will attend for follow- up at 1 week, 3 weeks, 
6 weeks and 12 weeks, 6 months, 9 months and 12 months 
post- randomisation. At all follow- up visits, a clinical assess-
ment will be undertaken and a photograph and planim-
etry tracing of the ulcer will be collected (unless healing 
has been confirmed). The EQ- 5D and the CCVUQ will 
be collected at baseline and the 12- week, 6- month and 
12- month follow- ups. Healthcare- resource use (proce-
dures, hospital, general practitioner and community 
nurse visits, physiotherapy and other interventions), days 
lost from work and normal activities, carer time and out- 
of- pocket expenses related to leg ulcer care will also be 
collected from case notes and patient diaries during the 
initial procedure and at 6 and 12 months.
Fortnightly calls will be made after the 6- week follow- up 
to check if the ulcer has healed. If the participant reports 
that their ulcer has healed, they will be invited to attend 
a verification visit, where a photograph of the ulcer will 
be taken. This photograph will be sent to an indepen-
dent assessor (blinded to treatment allocation) for assess-
ment and confirmation of healing status. Ulcer healing 
is defined as complete re- epithelialisation of the index 
ulcer in the absence of a scab (eschar) with no dressing 
required confirmed by blinded photo assessment of 
healing.
If the ulcer is confirmed as healed, monthly telephone 
calls will be performed to check for recurrence. In the 
event that an ulcer is confirmed as healed, the recur-
rence, safety, resource use and health questionnaire data 
can be collected over the telephone or by post. If the 
participant fails to attend their appointment, attempts 
will be made to collect the QoL and patient resource- use 
diaries by telephone or post. Participants will receive up 
to £10 for each visit attended as a contribution towards 
travel expenses.
Data collection and confidentiality
Participant data will be stored in the password- protected 
REDCap database. Participant details will be anonymised 
as each participant will be allocated a participant number. 
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Identifiable data, including contact information, will also 
be recorded on paper forms and will be kept in a locked 
filing cabinet in a locked office at each investigational 
site. Data will be monitored for quality and completeness 
and missing data will be requested from the participating 
sites, as per the data monitoring plan.
Statistical analysis
All analyses will be carried out on an intention- to- treat 
(ITT) basis. A mixed- effects, logistic regression on the 
outcome of the proportion of those with the index ulcer 
healed at 12 weeks, with site as a random effect and 
randomised group as the treatment effect, along with 
index ulcer size and duration at baseline (the minimis-
ation factors) and any other baseline factors known or 
suspected to be strongly related to good or poor outcome, 
will form the model. Goodness of model fit will be exam-
ined using the Hosmer- Lemeshow approach. The robust-
ness of the findings to any patterns of missing data (both 
assuming data are missing at random; and, if appropriate, 
informatively missing (missing not at random)) will be 
explored using appropriate sensitivity analyses.
Secondary outcomes (including the primary outcome 
at 12 months, time to index ulcer healing, reduction in 
ulcer area at 12 weeks, ulcer recurrence at 12 months 
and QoL) will be assessed using various statistical models 
appropriate to the distribution and nature of these 
outcomes, with the same modelling strategy as per the 
primary outcome above (eg, missing data and appro-
priate model diagnostics).
The proportion healed at 12 months and the recur-
rence of the index ulcer at 12 months will be analysed 
as the primary outcome above. The time to index ulcer 
healing will be analysed using a survival- type model (eg, 
Cox proportional hazards model), and if the assumption 
regarding proportional hazards fails, using a Restricted 
Mean Survival Time approach. The reduction in area of 
the index ulcer at 12 weeks over baseline will be analysed 
using a linear mixed model. The QoL data (EQ- 5D and 
CCVUQ questionnaire) will be analysed using repeated 
measures mixed linear models (with repeated measures 
at 12 weeks, 6 months and 12 months and a suitable spec-
ified covariance structure), with the overall treatment 
effect and the evolution of any treatment effect over time 
modelled.
Cost-effectiveness analysis
A literature review will be conducted to identify other 
economic studies and other trials in comparable popu-
lations. A within- trial analysis and a decision model will 
be constructed. In both cases, the main analyses will be 
performed from the perspective of the NHS and Personal 
Social Services. Secondary analyses will be performed from 
a societal perspective. The price year will be 2018–2019. 
Discounting will be applied according to the UK govern-
ment guidelines. The study will be reported according to 
Consolidated Guidelines for Economic Evaluation.43
The within- trial analysis will compare the treatment 
strategies within the 12- month time horizon of the clin-
ical trial on an ITT basis. Data will be collected by case 
note review and questionnaires completed at baseline 
and follow- up.
Resource- use items in hospital and community care, 
adverse events (AEs) or complications will be recorded 
for each patient at 6 and 12 months. Resource use will 
be multiplied by UK unit costs obtained from published 
literature, Healthcare Resource Groups and manufac-
turers’ list prices to calculate overall costs. Utilities and 
QALYs will be calculated from the EQ- 5D questionnaire. 
The extent of missing data will be assessed and appro-
priate methods to handle missing data will be applied.
The decision model provides a framework to incorpo-
rate evidence from other relevant studies and to extrap-
olate outcomes, such as ulcer healing and recurrence, 
beyond the trial reporting period. The Markov model 
will include the key ulcer- related health states and events 
that may occur during the lifetime of the patient. The 
data to support extrapolation may be taken from the trial 
(eg, fitting parametric time- to- event functions to the trial 
data) or may come from external sources (such as the 
literature review or observational data).44 45
In both the within- trial and model analyses, the ICER 
will be calculated and compared with current UK decision- 
making thresholds. Sensitivity analysis will be carried out 
to test the robustness of results to alternative assumptions 
about model structure or data. The cost- effectiveness 
acceptability curve will be calculated using probabilistic 
sensitivity analysis.43
Data monitoring, safety and quality control
An independent TSC and independent Data Monitoring 
Committee (iDMC) have been appointed. The main role 
of the TSC is to provide overall supervision of the trial 
and ensure that it is being conducted in accordance with 
the principles of Good Clinical Practice and the relevant 
regulations, while the main role of the iDMC is to safe-
guard the interests of trial participants and to monitor 
the main outcome measures including safety and efficacy. 
A clinical trial manager, together with the Trial Manage-
ment Group, will oversee trial progress.
All treatment- related AEs (related to the skin graft or 
leg ulcer only) will be collected as will all serious AEs 
(SAEs). The chief investigator (CI) will be notified of all 
SAEs within 24 hours. All SAEs will be reported to the 
research ethics committee if, in the opinion of the CI, 
the event was related to the intervention. All related AEs 
and SAEs will be recorded and summarised by treatment 
strategy. These analyses will be descriptive, with any p 
values calculated to be interpreted descriptively.
DISCUSSION
Although compression therapy is the mainstay of treat-
ment, there is a need to explore new treatments for 
wounds that are chronic and persistent in nature. This is 
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the first randomised controlled trial to evaluate the use of 
DCD allograft for the treatment of VLU. This study will 
provide important data on whether the use of the DCD 
allograft plus standard care is associated with improved 
outcomes compared with standard care alone and will 
provide important data on its effects on QoL and health-
care costs.
Patient and public involvement
Focus groups were held with patients accessing the 
vascular clinic at Imperial College Healthcare NHS Trust 
to obtain views on the proposed study and the accept-
ability of the DCD allograft. The focus group helped 
to inform important aspects of the trial, including the 
number of visits and questionnaires used in the study. A 
Patient and Public Involvement (PPI) representative was 
included as a co- applicant and provided invaluable input 
in the study design. A PPI representative also sits on the 
TSC, providing real- time input on study progress. He will 
also aid with dissemination of the results.
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